Identification

Name
Pseudoephedrine
Accession Number
DB00852  (APRD00634)
Type
Small Molecule
Groups
Approved
Description

An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.

Structure
Thumb
Synonyms
  • (+) threo-2-(methylamino)-1-phenyl-1-propanol
  • (+)-(1S,2S)-Pseudoephedrine
  • (+)-Pseudoephedrine
  • (+)-psi-Ephedrine
  • (+)-threo-Ephedrine
  • d-Isoephedrine
  • d-Pseudoephedrine
  • d-psi-2-Methylamino-1-phenyl-1-propanol
  • d-psi-Ephedrine
  • Isoephedrine
  • L-(+)-Pseudoephedrine
  • L(+)-psi-Ephedrine
  • Pseudoefedrina
  • pseudoéphédrine
  • Pseudoephedrine D-form
  • Pseudoephedrinum
  • Psi-ephedrin
  • Psi-ephedrine
  • trans-Ephedrine
  • ψ-ephedrine
Product Ingredients
IngredientUNIICASInChI Key
Pseudoephedrine hydrochloride6V9V2RYJ8N345-78-8BALXUFOVQVENIU-KXNXZCPBSA-N
Pseudoephedrine sulfateY9DL7QPE6B7460-12-0XVPDSDYVNYOVMP-KXNXZCPBSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SudoGestTablet, film coated60 mg/1Oralbryant ranch prepack1994-10-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
12 Hour DecongestantTablet, film coated, extended release120 mg/1OralL. Perrigo Company2011-10-04Not applicableUs
12 Hour DecongestantTablet, film coated, extended release120 mg/1OralKroger1999-12-14Not applicableUs
12 Hour DecongestantTablet, film coated, extended release120 mg/1OralMeijer Distribution1999-11-05Not applicableUs
12 Hour Nasal DecongestantTablet, film coated, extended release120 mg/1OralCvs Health1999-12-01Not applicableUs
12 Hour Nasal Decongestant Non DrowsyTablet, film coated, extended release120 mg/1OralSafeway2000-05-25Not applicableUs
Balminil Decongestionnant Sirop 30mg/5mlSyrup30 mgOralRougier Pharma Division Of Ratiopharm Inc1988-12-312000-09-07Canada
Benylin D for InfantsSyrup7.5 mgOralPfizer Canada Inc., Consumer Healthcare Division2004-08-092006-08-03Canada
Care One Suphedrine Nasal Decongestant Non DrowsyTablet, film coated30 mg/1OralAmerican Sales Company2003-12-01Not applicableUs
CareOne Nasal and Sinus DecongestantTablet, film coated, extended release120 mg/1OralAmerican Sales Company2016-09-15Not applicableUs
Careone Suphedrine 12 Hour Relief Non DrowsyTablet, film coated, extended release120 mg/1OralAmerican Sales Company2004-05-11Not applicableUs
International/Other Brands
Afrinol / Benylin Decongestant / Cenafed / Decofed / Dimetapp Decongestant / Eltor 120 / Genaphed / Maxenal / Myfedrine / Novafed / Robidrine / Sudafed Decongestant
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
12 Hour Allergy DPseudoephedrine hydrochloride (120 mg/1) + Cetirizine hydrochloride (5 mg/1)Tablet, extended releaseOralMeijer Distribution1988-07-15Not applicableUs
A.M. Cold Relief FormulaPseudoephedrine hydrochloride (30.0 mg) + Acetaminophen (325.0 mg) + Dextromethorphan hydrobromide (15.0 mg)CapsuleOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Abanatuss PedPseudoephedrine hydrochloride (60 mg/5mL) + Chlophedianol hydrochloride (25 mg/5mL) + Dexchlorpheniramine maleate (2 mg/5mL)SolutionOralKramer Novis.2015-07-01Not applicableUs
Abanatuss Ped DropsPseudoephedrine hydrochloride (15 mg/mL) + Chlophedianol hydrochloride (6.25 mg/mL) + Dexchlorpheniramine maleate (.5 mg/mL)SolutionOralKramer Novis.2015-08-05Not applicableUs
Abatuss DmxPseudoephedrine hydrochloride (30 mg/5mL) + Dexchlorpheniramine maleate (1 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL)LiquidOralKramer Novis.2014-05-25Not applicableUs
Acetaminophen/dextromethorphan/pseudoephedrinePseudoephedrine hydrochloride (30 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg)CapsuleOralApotex CorporationNot applicableNot applicableCanada
Acetaminophen/pseudoephedrine/dextromethorphan/doxylaminePseudoephedrine hydrochloride (30 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg) + Doxylamine succinate (6.25 mg)CapsuleOralApotex CorporationNot applicableNot applicableCanada
ActiconPseudoephedrine hydrochloride (60 mg/1) + Dexbrompheniramine maleate (2 mg/1)TabletOralActipharma, Inc2015-08-13Not applicableUs
ActiconPseudoephedrine hydrochloride (30 mg/5mL) + Dexbrompheniramine maleate (1 mg/5mL)LiquidOralActipharma, Inc2016-07-14Not applicableUs
Actifed DM SyrupPseudoephedrine hydrochloride (30 mg) + Dextromethorphan hydrobromide (15 mg) + Triprolidine hydrochloride (1.25 mg)SyrupOralGlaxo Wellcome1980-12-312000-08-03Canada
Categories
UNII
7CUC9DDI9F
CAS number
90-82-4
Weight
Average: 165.2322
Monoisotopic: 165.115364107
Chemical Formula
C10H15NO
InChI Key
KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
IUPAC Name
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
SMILES
CN[[email protected]@H](C)[[email protected]@H](O)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism.

Structured Indications
Pharmacodynamics

Pseudoephedrine is a sympathomimetic agent, structurally similar to ephedrine, used to relieve nasal and sinus congestion and reduce air-travel-related otalgia in adults. The salts pseudoephedrine hydrochloride and pseudoephedrine sulfate are found in many over-the-counter preparations either as single-ingredient preparations, or more commonly in combination with antihistamines and/or paracetamol/ibuprofen. Unlike antihistamines, which modify the systemic histamine-mediated allergic response, pseudoephedrine only serves to relieve nasal congestion commonly associated with colds or allergies. The advantage of oral pseudoephedrine over topical nasal preparations, such as oxymetazoline, is that it does not cause rebound congestion (rhinitis medicamentosa).

Mechanism of action

Pseudoephedrine acts directly on both alpha- and, to a lesser degree, beta-adrenergic receptors. Through direct action on alpha-adrenergic receptors in the mucosa of the respiratory tract, pseudoephedrine produces vasoconstriction. Pseudoephedrine relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors. Like ephedrine, pseudoephedrine releasing norepinephrine from its storage sites, an indirect effect. This is its main and direct mechanism of action. The displaced noradrenaline is released into the neuronal synapse where it is free to activate the postsynaptic adrenergic receptors.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent dopamine transporter
inhibitor
Human
AAlpha-1A adrenergic receptor
agonist
Human
AAlpha-2A adrenergic receptor
agonist
Human
ASodium-dependent serotonin transporter
inhibitor
Human
UBeta-2 adrenergic receptor
partial agonist
Human
UBeta-1 adrenergic receptor
agonist
partial agonist
Human
UNuclear factor of activated T-cells, cytoplasmic 1Not AvailableHuman
UTumor necrosis factorNot AvailableHuman
UNuclear factor kappa-light-chain-enhancer of activated B cellsNot AvailableHuman
Uactivator protein 1Not AvailableHuman
UInterleukin-2Not AvailableHuman
Absorption

Pseudoephedrine is readily and almost completely absorbed from the GI tract and there is no evidence of first-pass metabolism.

Volume of distribution
Not Available
Protein binding

Pseudoephedrine does not bind to human plasma proteins over the concentration range of 50 to 2000 ng/mL

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

9-16 hours

Clearance
Not Available
Toxicity

Common adverse reactions include nervousness, restlessness, and insomnia. Rare adverse reactions include difficult/painful urination, dizziness/lightheadedness, heart palpitations, headache, increased sweating, nausea/vomiting, trembling, troubled breathing, unusual paleness, and weakness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Pseudoephedrine.Experimental
AbirateroneThe serum concentration of Pseudoephedrine can be increased when it is combined with Abiraterone.Approved
AcebutololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Pseudoephedrine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Pseudoephedrine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Pseudoephedrine.Approved
AcrivastinePseudoephedrine may decrease the sedative activities of Acrivastine.Approved
AlcaftadinePseudoephedrine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilPseudoephedrine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved, Investigational
AlgeldrateAlgeldrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
AlimemazinePseudoephedrine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
AloglutamolAloglutamol may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
AlphacetylmethadolPseudoephedrine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodinePseudoephedrine may increase the analgesic activities of Alphaprodine.Illicit
AlprenololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Pseudoephedrine.Illicit, Withdrawn
AmiodaroneThe metabolism of Pseudoephedrine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may decrease the stimulatory activities of Pseudoephedrine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
Ammonium chlorideThe serum concentration of Pseudoephedrine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Pseudoephedrine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Pseudoephedrine.Approved, Illicit
AntazolinePseudoephedrine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved, Investigational
ArotinololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ArtemetherThe metabolism of Pseudoephedrine can be decreased when combined with Artemether.Approved
AsenapineAsenapine may decrease the stimulatory activities of Pseudoephedrine.Approved
AstemizolePseudoephedrine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtenololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Pseudoephedrine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Pseudoephedrine.Vet Approved
AzatadinePseudoephedrine may decrease the sedative activities of Azatadine.Approved
AzelastinePseudoephedrine may decrease the sedative activities of Azelastine.Approved
BamipinePseudoephedrine may decrease the sedative activities of Bamipine.Experimental
BefunololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Pseudoephedrine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Pseudoephedrine.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pseudoephedrine.Approved, Illicit
Benzylpenicilloyl PolylysinePseudoephedrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetaxololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BezitramidePseudoephedrine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Pseudoephedrine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
BisoprololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Brofaromine.Experimental
BromocriptineBromocriptine may increase the hypertensive activities of Pseudoephedrine.Approved, Investigational
BromperidolBromperidol may decrease the stimulatory activities of Pseudoephedrine.Investigational
BrompheniraminePseudoephedrine may decrease the sedative activities of Brompheniramine.Approved
BucindololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BuclizinePseudoephedrine may decrease the sedative activities of Buclizine.Approved
BufuralolPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Pseudoephedrine.Investigational
BupranololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphinePseudoephedrine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Pseudoephedrine can be decreased when combined with Bupropion.Approved
ButaperazineButaperazine may decrease the stimulatory activities of Pseudoephedrine.Experimental
ButorphanolPseudoephedrine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidPseudoephedrine may decrease the sedative activities of Butyric Acid.Experimental
CabergolineCabergoline may increase the hypertensive activities of Pseudoephedrine.Approved
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
CarbinoxaminePseudoephedrine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilPseudoephedrine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Pseudoephedrine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Pseudoephedrine.Withdrawn
CarteololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Pseudoephedrine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CetirizinePseudoephedrine may decrease the sedative activities of Cetirizine.Approved
ChloropyraminePseudoephedrine may decrease the sedative activities of Chloropyramine.Approved
ChloroquineThe metabolism of Pseudoephedrine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenaminePseudoephedrine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxaminePseudoephedrine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Pseudoephedrine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Pseudoephedrine.Experimental
ChlorpromazineThe metabolism of Pseudoephedrine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Pseudoephedrine.Approved, Withdrawn
CholecalciferolThe metabolism of Pseudoephedrine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Pseudoephedrine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Pseudoephedrine can be decreased when combined with Cinacalcet.Approved
CinnarizinePseudoephedrine may decrease the sedative activities of Cinnarizine.Approved
CitalopramThe metabolism of Pseudoephedrine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Pseudoephedrine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Pseudoephedrine.Approved, Vet Approved
ClobazamThe metabolism of Pseudoephedrine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Pseudoephedrine.Experimental
CloranololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Pseudoephedrine.Experimental
ClotrimazoleThe metabolism of Pseudoephedrine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Pseudoephedrine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Pseudoephedrine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pseudoephedrine can be decreased when combined with Cocaine.Approved, Illicit
CodeinePseudoephedrine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Pseudoephedrine.Approved
CyclizinePseudoephedrine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Pseudoephedrine.Approved
CyproheptadinePseudoephedrine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
DarifenacinThe metabolism of Pseudoephedrine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Pseudoephedrine can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Pseudoephedrine can be decreased when combined with Delavirdine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
DesloratadinePseudoephedrine may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Pseudoephedrine.Approved
DexbrompheniraminePseudoephedrine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniraminePseudoephedrine may decrease the sedative activities of Dexchlorpheniramine.Experimental
Dexchlorpheniramine maleatePseudoephedrine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramidePseudoephedrine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePseudoephedrine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocinePseudoephedrine may increase the analgesic activities of Dezocine.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Pseudoephedrine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
DihydrocodeinePseudoephedrine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Pseudoephedrine.Approved
DihydroetorphinePseudoephedrine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePseudoephedrine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinatePseudoephedrine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindenePseudoephedrine may decrease the sedative activities of Dimetindene.Approved
DimetotiazinePseudoephedrine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineThe metabolism of Pseudoephedrine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylatePseudoephedrine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Pseudoephedrine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Pseudoephedrine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Pseudoephedrine.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Pseudoephedrine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Pseudoephedrine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Doxofylline.Approved
DoxylaminePseudoephedrine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEPseudoephedrine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Pseudoephedrine.Approved, Illicit
DronedaroneThe metabolism of Pseudoephedrine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may decrease the stimulatory activities of Pseudoephedrine.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Pseudoephedrine.Approved
EbastinePseudoephedrine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Pseudoephedrine.Investigational
EliglustatThe metabolism of Pseudoephedrine can be decreased when combined with Eliglustat.Approved
EmedastinePseudoephedrine may decrease the sedative activities of Emedastine.Approved
EpanololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Pseudoephedrine.Approved
EpinastinePseudoephedrine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Pseudoephedrine.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Pseudoephedrine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Pseudoephedrine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Pseudoephedrine.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Pseudoephedrine.Investigational
EsmololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EthopropazinePseudoephedrine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Pseudoephedrine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Withdrawn
EthylmorphinePseudoephedrine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Pseudoephedrine.Withdrawn
EtorphinePseudoephedrine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidinePseudoephedrine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Pseudoephedrine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Pseudoephedrine.Approved
FenozoloneThe risk or severity of adverse effects can be increased when Fenozolone is combined with Pseudoephedrine.Experimental
FentanylPseudoephedrine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadinePseudoephedrine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Pseudoephedrine.Experimental
FlunarizinePseudoephedrine may decrease the sedative activities of Flunarizine.Approved
FluoxetineThe metabolism of Pseudoephedrine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Pseudoephedrine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Pseudoephedrine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Pseudoephedrine.Approved
FluvoxamineThe metabolism of Pseudoephedrine can be decreased when combined with Fluvoxamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Pseudoephedrine.Approved, Vet Approved
Glutamic AcidThe serum concentration of Pseudoephedrine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Pseudoephedrine can be decreased when it is combined with Guanethidine.Approved
HaloperidolThe metabolism of Pseudoephedrine can be decreased when combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Harmaline.Experimental
HeroinPseudoephedrine may increase the analgesic activities of Heroin.Approved, Illicit
HydracarbazineHydracarbazine may increase the hypertensive activities of Pseudoephedrine.Experimental
HydrocodonePseudoephedrine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphonePseudoephedrine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Pseudoephedrine.Approved
HydroxyzinePseudoephedrine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
ImipramineImipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
IndenololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Pseudoephedrine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Pseudoephedrine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Pseudoephedrine.Approved
Ioflupane I-123Pseudoephedrine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may decrease the antihypertensive activities of Pseudoephedrine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Pseudoephedrine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Pseudoephedrine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Pseudoephedrine.Approved
IsoniazidThe metabolism of Pseudoephedrine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Pseudoephedrine.Approved
IsothipendylPseudoephedrine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Pseudoephedrine.Approved, Withdrawn
KetobemidonePseudoephedrine may increase the analgesic activities of Ketobemidone.Approved
KetoconazoleThe metabolism of Pseudoephedrine can be decreased when combined with Ketoconazole.Approved, Investigational
KetotifenPseudoephedrine may decrease the sedative activities of Ketotifen.Approved
LabetalolPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LafutidinePseudoephedrine may decrease the sedative activities of Lafutidine.Investigational
LandiololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LavoltidinePseudoephedrine may decrease the sedative activities of Lavoltidine.Investigational
LevocabastinePseudoephedrine may decrease the sedative activities of Levocabastine.Approved
LevocetirizinePseudoephedrine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetatePseudoephedrine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Pseudoephedrine.Approved
LevorphanolPseudoephedrine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Pseudoephedrine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Pseudoephedrine.Approved
LodoxamidePseudoephedrine may decrease the sedative activities of Lodoxamide.Approved
LofentanilPseudoephedrine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Pseudoephedrine.Experimental
LopinavirThe metabolism of Pseudoephedrine can be decreased when combined with Lopinavir.Approved
LoratadinePseudoephedrine may decrease the sedative activities of Loratadine.Approved
LorcaserinThe metabolism of Pseudoephedrine can be decreased when combined with Lorcaserin.Approved
LoxapineLoxapine may decrease the stimulatory activities of Pseudoephedrine.Approved
LumefantrineThe metabolism of Pseudoephedrine can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Pseudoephedrine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
ManidipineThe metabolism of Pseudoephedrine can be decreased when combined with Manidipine.Approved
MebanazineMebanazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
MeclizinePseudoephedrine may decrease the sedative activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Mefenorex is combined with Pseudoephedrine.Experimental
MelperoneMelperone may decrease the stimulatory activities of Pseudoephedrine.Approved
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Pseudoephedrine.Approved
MepindololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MeptazinolPseudoephedrine may increase the analgesic activities of Meptazinol.Experimental
MepyraminePseudoephedrine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazinePseudoephedrine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Pseudoephedrine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Pseudoephedrine.Approved, Investigational
MethadoneThe metabolism of Pseudoephedrine can be decreased when combined with Methadone.Approved
Methadyl AcetatePseudoephedrine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Pseudoephedrine.Approved, Illicit
MethapyrilenePseudoephedrine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
MethenamineThe serum concentration of Pseudoephedrine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineThe metabolism of Pseudoephedrine can be decreased when combined with Methotrimeprazine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Pseudoephedrine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Pseudoephedrine.Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Pseudoephedrine.Approved
MetiamidePseudoephedrine may decrease the sedative activities of Metiamide.Experimental
MetoprololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MianserinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Mianserin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Pseudoephedrine.Approved
MidostaurinThe metabolism of Pseudoephedrine can be decreased when combined with Midostaurin.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Pseudoephedrine.Approved
MinaprineMinaprine may increase the hypertensive activities of Pseudoephedrine.Approved
MirabegronThe metabolism of Pseudoephedrine can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Pseudoephedrine.Approved
MizolastinePseudoephedrine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Pseudoephedrine.Approved
MolindoneMolindone may decrease the stimulatory activities of Pseudoephedrine.Approved
MoperoneMoperone may decrease the stimulatory activities of Pseudoephedrine.Experimental
MorphinePseudoephedrine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Pseudoephedrine.Experimental
NabiloneNabilone may increase the tachycardic activities of Pseudoephedrine.Approved, Investigational
NadololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphinePseudoephedrine may increase the analgesic activities of Nalbuphine.Approved
NevirapineThe metabolism of Pseudoephedrine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Pseudoephedrine.Withdrawn
NicardipineThe metabolism of Pseudoephedrine can be decreased when combined with Nicardipine.Approved
NicomorphinePseudoephedrine may increase the analgesic activities of Nicomorphine.Experimental
NilotinibThe metabolism of Pseudoephedrine can be decreased when combined with Nilotinib.Approved, Investigational
NizatidinePseudoephedrine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Pseudoephedrine.Approved
NormethadonePseudoephedrine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pseudoephedrine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Pseudoephedrine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Pseudoephedrine.Approved, Investigational
OlopatadinePseudoephedrine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Pseudoephedrine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Pseudoephedrine.Investigational
OpiumPseudoephedrine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Pseudoephedrine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Pseudoephedrine.Investigational
OxatomidePseudoephedrine may decrease the sedative activities of Oxatomide.Investigational
OxprenololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxycodonePseudoephedrine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pseudoephedrine.Approved
OxymorphonePseudoephedrine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Pseudoephedrine.Experimental
OzagrelPseudoephedrine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
PanobinostatThe serum concentration of Pseudoephedrine can be increased when it is combined with Panobinostat.Approved, Investigational
PargylinePargyline may increase the hypertensive activities of Pseudoephedrine.Approved
ParoxetineThe metabolism of Pseudoephedrine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Pseudoephedrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PemirolastPseudoephedrine may decrease the sedative activities of Pemirolast.Approved
PenbutololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Pseudoephedrine.Experimental
PentazocinePseudoephedrine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Pseudoephedrine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Pseudoephedrine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PethidinePseudoephedrine may increase the analgesic activities of Pethidine.Approved
PhenazocinePseudoephedrine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Pseudoephedrine.Approved
PhenindaminePseudoephedrine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
PheniraminePseudoephedrine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Pseudoephedrine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Pseudoephedrine.Approved
PhenoperidinePseudoephedrine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Pseudoephedrine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Pseudoephedrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Pseudoephedrine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Pseudoephedrine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Pseudoephedrine.Approved
PindololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperonePipamperone may decrease the stimulatory activities of Pseudoephedrine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PiritramidePseudoephedrine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Pseudoephedrine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
PractololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Prenalterol is combined with Pseudoephedrine.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Pseudoephedrine.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Pseudoephedrine.Approved, Vet Approved
PromazineThe metabolism of Pseudoephedrine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePseudoephedrine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PropranololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of Pseudoephedrine.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuifenadinePseudoephedrine may decrease the sedative activities of Quifenadine.Experimental
QuinidineThe metabolism of Pseudoephedrine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Pseudoephedrine can be decreased when combined with Quinine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Pseudoephedrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Pseudoephedrine.Investigational
RanitidinePseudoephedrine may decrease the sedative activities of Ranitidine.Approved
RanolazineThe metabolism of Pseudoephedrine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Pseudoephedrine.Approved
RemifentanilPseudoephedrine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Pseudoephedrine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Pseudoephedrine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Pseudoephedrine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Pseudoephedrine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Pseudoephedrine.Approved
RitonavirThe metabolism of Pseudoephedrine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Pseudoephedrine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Pseudoephedrine can be decreased when combined with Ropinirole.Approved, Investigational
Roxatidine acetatePseudoephedrine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Pseudoephedrine.Approved, Withdrawn
SertralineThe metabolism of Pseudoephedrine can be decreased when combined with Sertraline.Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
SotalolPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Pseudoephedrine.Approved
StiripentolThe metabolism of Pseudoephedrine can be decreased when combined with Stiripentol.Approved
SufentanilPseudoephedrine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Pseudoephedrine.Approved
SultoprideSultopride may decrease the stimulatory activities of Pseudoephedrine.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Pseudoephedrine.Experimental
TalinololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved, Investigational
TapentadolPseudoephedrine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Pseudoephedrine.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
TerbinafineThe metabolism of Pseudoephedrine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Pseudoephedrine.Approved
TerfenadinePseudoephedrine may decrease the sedative activities of Terfenadine.Withdrawn
TertatololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TesmilifenePseudoephedrine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Pseudoephedrine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Pseudoephedrine.Approved
ThiopropazateThiopropazate may decrease the stimulatory activities of Pseudoephedrine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Pseudoephedrine.Approved
ThioridazineThe metabolism of Pseudoephedrine can be decreased when combined with Thioridazine.Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Pseudoephedrine.Approved
ThonzylaminePseudoephedrine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Pseudoephedrine.Approved
TiaprideTiapride may decrease the stimulatory activities of Pseudoephedrine.Approved, Investigational
TiclopidineThe metabolism of Pseudoephedrine can be decreased when combined with Ticlopidine.Approved
TilidinePseudoephedrine may increase the analgesic activities of Tilidine.Experimental
TimololPseudoephedrine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TipranavirThe metabolism of Pseudoephedrine can be decreased when combined with Tipranavir.Approved, Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Pseudoephedrine.Approved
TramadolPseudoephedrine may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Tramazoline is combined with Pseudoephedrine.Investigational
TranilastPseudoephedrine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Pseudoephedrine.Experimental
TranylcypromineThe metabolism of Pseudoephedrine can be decreased when combined with Tranylcypromine.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Tretoquinol is combined with Pseudoephedrine.Experimental
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Pseudoephedrine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Pseudoephedrine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Pseudoephedrine.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Pseudoephedrine.Experimental
TrimipramineTrimipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
TripelennaminePseudoephedrine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidinePseudoephedrine may decrease the sedative activities of Triprolidine.Approved
TritoqualinePseudoephedrine may decrease the sedative activities of Tritoqualine.Experimental
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Pseudoephedrine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Pseudoephedrine.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Pseudoephedrine.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Pseudoephedrine.Experimental
Vitamin CThe serum concentration of Pseudoephedrine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneThe metabolism of Pseudoephedrine can be decreased when combined with Ziprasidone.Approved
ZotepineZotepine may decrease the stimulatory activities of Pseudoephedrine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Pseudoephedrine.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Andrew G. Myers, "Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary." U.S. Patent US5760237, issued June, 1991.

US5760237
General References
Not Available
External Links
Human Metabolome Database
HMDB01943
KEGG Drug
D08449
KEGG Compound
C02765
PubChem Compound
7028
PubChem Substance
46508190
ChemSpider
6761
ChEBI
51209
ChEMBL
CHEMBL1590
Therapeutic Targets Database
DAP000195
PharmGKB
PA451170
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pseudoephedrine
ATC Codes
R01BA02 — PseudoephedrineR01BA52 — Pseudoephedrine, combinations
AHFS Codes
  • 12:12.12 — Alpha-and Beta-adrenergic Agonists
  • 28:28.00 — Antimanic Agents
  • 48:08.00 — Antitussives
  • 04:04.04 — Ethanolamine Derivatives
  • 48:16.00 — Expectorants
  • 28:08.92 — Miscellaneous Analgesics and Antipyretics
  • 04:04.92 — Miscellaneous Derivatives
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
  • 04:04.12 — Phenothiazine Derivatives
  • 04:04.20 — Propylamine Derivatives
  • 04:08.00 — Second Generation Antihistamines
  • 12:12.00 — Sympathomimetic (Adrenergic) Agents
MSDS
Download (52.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingOtherMultiple System Atrophy (MSA) / Shy-Drager Syndrome1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedDiagnosticBMI >30 kg/m2 / Hypertensive / Progressive autonomic failure / Shy-Drager Syndrome1
1CompletedTreatmentHealthy Volunteers5
2CompletedTreatmentAllergic Rhinitis (AR)3
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
2Unknown StatusTreatmentRhinitis, Seasonal, Allergic1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sinusitis1
3CompletedTreatmentNasal Congestion Associated With the Common Cold1
3CompletedTreatmentNasal Congestion and Inflammations / Rhinitis1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentAcute Rhinitis / Pharyngitis1
3CompletedTreatmentRhinitis, Allergic, Perennial1
3CompletedTreatmentRhinitis, Allergic, Seasonal1
3CompletedTreatmentSeasonal Rhinitis1
3CompletedTreatmentVasomotor Rhinitis1
3CompletedTreatmentAcute Rhinitis1
3Unknown StatusTreatmentViral Infections of the Upper Respiratory Tract1
3WithdrawnTreatmentCoughing / Inflammatory Reaction / Rhinitis1
4CompletedPreventionAcute Upper Respiratory Track Infection1
4CompletedTreatmentAcute Respiratory Infections / Acute Rhinosinusitis1
4CompletedTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Acute Respiratory Infections / Bronchitis1
4CompletedTreatmentAcute Rhinitis / Headaches / Nasal Stuffiness1
4CompletedTreatmentNasal Stuffiness1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableSeasonal Allergic Rhinitis (SAR) / Sinusitis1
Not AvailableCompletedBasic ScienceUrethral Sphincter Activity1
Not AvailableCompletedTreatmentAtopics / Rhinitis1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sinusitis1
Not AvailableCompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
Not AvailableRecruitingBasic ScienceMiddle Ear Disease / Nasal Allergies1
Not AvailableUnknown StatusTreatmentCoughing1
Not AvailableUnknown StatusTreatmentRhinitis / Sleep1

Pharmacoeconomics

Manufacturers
  • Ucb inc
  • Schering plough healthcare products inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral120 mg/1
Capsule, liquid filledOral
Tablet, film coatedOral
SyrupOral7.5 mg
SyrupOral
SolutionOral15 mg/5mL
Tablet, extended releaseOral
Tablet, multilayer, extended releaseOral
Capsule; kitOral
TabletOral30 mg
Capsule, extended releaseOral120 mg
PillOral30 mg/1
Kit; powder, for solutionOral
Tablet; tablet, extended releaseOral
Tablet, extended releaseOral120 mg
LiquidOral60 mg/60mL
Kit; powderOral
SuspensionOral
Tablet, sugar coatedOral
PowderOral
SolutionOral
Tablet, coatedOral
Tablet, chewableOral
Tablet, film coated, extended releaseOral
TabletOral120 mg
Capsule, extended releaseOral240 mg
TabletOral
Capsule, gelatin coatedOral30 mg/1
TabletOral30 mg/1
Tablet, film coatedOral30 mg/1
Tablet, sugar coatedOral30 mg/1
LiquidOral
Capsule, extended releaseOral
Solution / dropsOral
Tablet, extended releaseOral120 mg/1
Tablet, film coatedOral120 mg/1
TabletOral60 mg/1
TabletOral60 mg
ElixirOral
Tablet, multilayerOral
CapsuleOral
LiquidOral30 mg/5mL
Tablet, extended releaseOral240 mg/1
TabletOral15 mg
SyrupOral30 mg
LiquidOral15 mg/5mL
Tablet, coatedOral30 mg/1
Tablet, film coatedOral60 mg/1
Powder, for solutionOral
Kit; tabletOral
LiquidOral30 mg
LiquidOral7.5 mg
Prices
Unit descriptionCostUnit
Sudafed 24 hour tablet0.84USD tablet
Pseudoephedrine hcl crystal0.67USD g
Afrin 0.05% nose spray0.62USD ml
Sudafed 12 hr sinus-pain caplet0.53USD caplet
Drixoral cold & allergy tablet sa0.4USD tablet
Sudafed om sinus nasal spray0.4USD ml
Afrin no drip sinus pump mist0.38USD ml
Sudafed pe cold & cough caplet0.34USD caplet
Afrin sinus spray0.33USD ml
Chlor-trimeton allergy0.31USD each
Sudafed pe severe cold caplet0.28USD caplet
Guaifenesin-phenylephrine tablet0.27USD tablet
Dimetapp cold-allergy tablet chew0.25USD tablet
Sudafed pe 10 mg tablet0.25USD tablet
Chlor-trimeton 8 mg repetab0.24USD tablet
Sudafed pe day & night tablet0.24USD tablet
Sudafed triple action caplet0.23USD caplet
Sudafed pe nighttime cold caplet0.22USD caplet
Sudafed non-drying sinus caplet0.2USD caplet
Sudafed pe sinus & allergy tablet0.2USD tablet
Sudafed pe sinus headache caplet0.2USD caplet
Sudafed 30 mg tablet0.19USD tablet
Wal-phed 30 mg tablet0.17USD tablet
Suphedrin 30 mg tablet0.15USD tablet
CVS Pharmacy decongestant 30 mg tablet0.12USD tablet
Sudogest 60 mg tablet0.12USD tablet
Medi-phedrine 30 mg tablet0.1USD tablet
Nasal decongestant 30 mg tablet0.1USD tablet
Genaphed plus tablet0.09USD tablet
CVS Pharmacy nasal decongest 30 mg tablet0.07USD tablet
Genaphed 30 mg tablet0.07USD tablet
Pseudoephedrine gg syrup0.07USD ml
Pseudoephedrine 60 mg tablet0.06USD tablet
Children's sudafed pe liquid0.05USD ml
Pseudoephedrine 30 mg tablet0.05USD tablet
Dimetapp cold & cough liquid0.04USD ml
Dimetapp dm cold & cough elix0.04USD ml
Dimetapp long-acting cough liquid0.04USD ml
Suphedrine 30 mg tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6037353Yes1997-09-142017-09-14Us
US6039974No1998-07-312018-07-31Us
US6211246No1999-06-102019-06-10Us
US6469009No1999-07-132019-07-13Us
US7226614No2002-06-102022-06-10Us
US6489329No1996-04-082016-04-08Us
US7014867No2002-06-102022-06-10Us
US6100274Yes2000-01-072020-01-07Us
US6372252No2000-04-282020-04-28Us
US6955821No2000-04-282020-04-28Us
US7838032No2000-04-282020-04-28Us
US7618649Yes2001-06-192021-06-19Us
US6709676No2001-02-182021-02-18Us
US8187630No2000-12-192020-12-19Us
US7863287No2007-02-282027-02-28Us
US6979463No2002-03-282022-03-28Us
US7820199Yes2002-09-282022-09-28Us
US6613357No2000-12-252020-12-25Us
USRE39069No1998-05-292018-05-29Us
US6113942Yes1995-08-282015-08-28Us
US5855912Yes1995-08-282015-08-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)119 °CPhysProp
water solubility7 mg/LNot Available
logP0.89KRIL,MB & FUNG,HL (1990)
pKa10.3 (at 0 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility8.26 mg/mLALOGPS
logP1ALOGPS
logP1.32ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)9.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area32.26 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity49.69 m3·mol-1ChemAxon
Polarizability18.83 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.5638
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7182
P-glycoprotein inhibitor INon-inhibitor0.9795
P-glycoprotein inhibitor IINon-inhibitor0.984
Renal organic cation transporterNon-inhibitor0.8965
CYP450 2C9 substrateNon-substrate0.8001
CYP450 2D6 substrateNon-substrate0.7839
CYP450 3A4 substrateNon-substrate0.7235
CYP450 1A2 substrateNon-inhibitor0.5595
CYP450 2C9 inhibitorNon-inhibitor0.7209
CYP450 2D6 inhibitorInhibitor0.5846
CYP450 2C19 inhibitorNon-inhibitor0.5737
CYP450 3A4 inhibitorNon-inhibitor0.9431
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.907
Ames testNon AMES toxic0.9517
CarcinogenicityNon-carcinogens0.7739
BiodegradationNot ready biodegradable0.7807
Rat acute toxicity2.3882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9329
hERG inhibition (predictor II)Non-inhibitor0.9277
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.24 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9000000000-8f0484f72b48017f1f2e
MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)LC-MS/MSsplash10-016s-3900000000-868bf4bba93d8b4be696
MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)LC-MS/MSsplash10-0159-2900000000-6c55fc67b7576cb42a8a
MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)LC-MS/MSsplash10-0006-9700000000-459686cbaf7d3b59c202
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Aralkylamines / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Phenylpropane / Aralkylamine / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Alcohol / Organopnictogen compound / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amine (CHEBI:51209) / Phenylalanine derived alkaloids (C02765)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Wee S, Ordway GA, Woolverton WL: Reinforcing effect of pseudoephedrine isomers and the mechanism of action. Eur J Pharmacol. 2004 Jun 16;493(1-3):117-25. [PubMed:15189772]
  2. Foley KF, Van Dort ME, Sievert MK, Ruoho AE, Cozzi NV: Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. J Neural Transm (Vienna). 2002 Oct;109(10):1229-40. [PubMed:12373557]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Wee S, Ordway GA, Woolverton WL: Reinforcing effect of pseudoephedrine isomers and the mechanism of action. Eur J Pharmacol. 2004 Jun 16;493(1-3):117-25. [PubMed:15189772]
  2. Foley KF, Van Dort ME, Sievert MK, Ruoho AE, Cozzi NV: Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. J Neural Transm (Vienna). 2002 Oct;109(10):1229-40. [PubMed:12373557]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wellington K, Jarvis B: Cetirizine/pseudoephedrine. Drugs. 2001;61(15):2231-40; discussion 2241-2. [PubMed:11772135]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Wee S, Ordway GA, Woolverton WL: Reinforcing effect of pseudoephedrine isomers and the mechanism of action. Eur J Pharmacol. 2004 Jun 16;493(1-3):117-25. [PubMed:15189772]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Vansal SS, Feller DR: Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol. 1999 Sep 1;58(5):807-10. [PubMed:10449190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
Partial agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Vansal SS, Feller DR: Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol. 1999 Sep 1;58(5):807-10. [PubMed:10449190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcriptional activator activity, rna polymerase ii distal enhancer sequence-specific binding
Specific Function
Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. ...
Gene Name
NFATC1
Uniprot ID
O95644
Uniprot Name
Nuclear factor of activated T-cells, cytoplasmic 1
Molecular Weight
101241.73 Da
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
References
  1. Wu Z, Kong X, Zhang T, Ye J, Fang Z, Yang X: Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-alpha-mediated acute liver failure induced by lipopolysaccharide/D-galactosamine. Eur J Pharmacol. 2014 Feb 5;724:112-21. doi: 10.1016/j.ejphar.2013.11.032. Epub 2013 Dec 21. [PubMed:24365491]
  2. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
10. Nuclear factor kappa-light-chain-enhancer of activated B cells
Kind
Protein
Organism
Human
Pharmacological action
Unknown
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
Transcriptional activator activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function
This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Binds to the Tax-responsive element (TRE) of HTLV-I. ...

Components:
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Kinase activator activity
Specific Function
Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimu...
Gene Name
IL2
Uniprot ID
P60568
Uniprot Name
Interleukin-2
Molecular Weight
17627.52 Da
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 09:34